Boston Scientific's second quarter revenue grew 7.5% to beat estimates, driven by strong Cardiovascular performance.

Boston Scientific reported second quarter 2026 net sales of $5.442 billion, a 7.5% year-over-year increase, and adjusted EPS of $0.86, up from $0.75 in the prior-year period. Both revenue and earnings per share surpassed analyst expectations.

Key Highlights

• Revenue grew 7.5% on a reported basis and 7.0% organically, exceeding the company's guidance range of 5% to 7% for organic growth.
• The Cardiovascular segment led performance, with net sales increasing 8.3% on a reported basis to $3.62 billion.
• Boston Scientific updated its full-year 2026 guidance, now expecting adjusted EPS between $3.28 and $3.32 and organic net sales growth of 5% to 6%.